

104 (92)

J19002 U.S. PTO
09/826069

| | | |
|--|-------|----------|
| | | Subclass |
| | Class | |

PATENT NUMBER

U.S. UTILITY Patent Application

| | | | |
|---|----------|------|-------------|
| 1 | O.I.P.E. | AA | PATENT DATE |
| | | | 10/22/02 |
| 1 | SCANNED | Q.A. | MM |

| | | | | | |
|------------------------------|-------------------|--------------|----------------|------------------|----------------------|
| APPLICATION NO. 09/826069 | CONT/PRIOR D F | CLASS 424 | SUBCLASS 67 | ART UNIT 1644 | EXAMINER J. V. J. |
|------------------------------|-------------------|--------------|----------------|------------------|----------------------|

APPlicants

Yakov Naparstek

三

Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus

PTO-2040
12/99

ISSUING CLASSIFICATION

| TERMINAL DISCLAIMER | DRAWINGS | | | CLAIMS ALLOWED | |
|---|--------------|-------------|------------|----------------------------|----------------------|
| | Sheets Drwg. | Figs. Drwg. | Print Fig. | Total Claims | Print Claim for O.G. |
| <input type="checkbox"/> The term of this patent subsequent to _____ (date) has been disclaimed. | | | | NOTICE OF ALLOWANCE MAILED | |
| <input type="checkbox"/> The term of this patent shall not extend beyond the expiration date of U.S Patent. No. _____ | | | | ISSUE FEE | |
| | | | | Amount Due | Date Paid |
| <input type="checkbox"/> The terminal _____ months of this patent have been disclaimed. | | | | ISSUE BATCH NUMBER | |
| | | | | | |

WARNING:

The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.

Form PTO-436A
(Rev. 6/99)

FILED WITH: DISK (CBF) FICHE CD-ROM

WPS Office 2019 Home and Student